Guardion Health: Surges on treatment for upper respiratory tract infections

Guardion Health Sciences

06/02/2020 13:04

** Shares of medical device maker  GHSI.O  jump 38% to 36
cents premarket; stock is biggest pct gainer across all U.S.
exchanges 
    ** Co says it has developed treatment targeting upper
respiratory tract infections  urn:newsml:reuters.com:*:nGNX7Bvqlx
    ** Efforts are being spearheaded by its recently acquired
NutriGuard business line that creates nutraceuticals, GHSI said
    ** Says new product, preliminarily labeled acuMMUNE, to be
introduced under NutriGuard label and will be initially offered
in a capsule in U.S. through its website
    ** GHSI expects sales of acuMMUNE to commence around April
    ** "This unique product can provide a timely and effective
immune response protocol to address respiratory tract symptoms
associated with global pandemics," Michael Favish, chief
executive officer said
    ** This comes at a time when coronavirus - a virus resulting
in fever, cough and breathing difficulties - has killed more
than 500 people in China and also spread to other countries
    ** acuMMUNE has been developed to treat excessive lung
inflammation leading to harsh symptoms and even death
    ** Up to Wednesday's close, stock has fallen 92.7% in last
12 months

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))